SGHT Sight Sciences, Inc. Insider Trading

Director Staffan Encrantz buys 14,100 shares of SGHT at $4.88, now trading -48.2% from 52-week high; prior same-ticker buys largely underperformed.

Encrantz purchased 14,100 shares at $4.88 on 2026-06-10, increasing his holdings to 1.43M shares. The stock currently trades at $4.79, down 48.2% from its 52-week high of $9.24, and has declined 2.8% over the past 30 days despite a 90-day gain of 30.5%. Notably, Encrantz's prior trades at SGHT have shown weak timing: of 5 prior buys at this ticker, only 1 was well-timed at the 90-day mark, with the most recent purchase (2025-12-16) experiencing a -55.0% 90-day decline. This purchase arrives as the company remains unprofitable (net income of $-13.0M in the latest quarter) with contracting annual revenue growth of -3.1%, creating a backdrop where the insider's accumulation pattern at this ticker has not reliably preceded price appreciation.

Director Staffan Encrantz purchases 13,958 shares of SGHT at $8.31; stock has gained 129.4% over 90 days amid unprofitable operations.

Director Staffan Encrantz purchased 13,958 shares at $8.31 on 2025-12-16, increasing his holdings from 1.38M to 1.39M shares. The purchase occurs within a volatile 90-day window where SGHT has gained 129.4%, though the stock currently trades at $8.26, 3.5% below its 52-week high of $8.56. His cross-ticker track record shows strong performance (78.95% 90-day win rate, +25.1% avg 90d return), but his same-ticker history at SGHT is mixed: only 2 of 5 prior buys achieved positive 90-day returns, with the most recent June 2025 purchases showing mixed near-term results. The company remains unprofitable with negative $8.2M annual net income and flat annual revenue growth (-1.5%), raising questions about the fundamental drivers of recent price appreciation and whether the insider's conviction extends to the company's operational outlook or reflects market momentum.

Director Encrantz Staffan bought 90,525 shares over 3 days at blended $4.22; holds 1,377,964 post-transaction.

Encrantz Staffan, a director at the unprofitable Sight Sciences, made 3 separate purchases totaling 90,525 shares for $381,957.97 over June 4–6, 2025, raising his holdings to 1.38M shares (+7.0% from pre-transaction levels). The buys occurred at $4.17, $4.24, and $4.22—prices near the current market price of $4.20—while the stock is down 49.5% from its 52-week high of $8.31 yet up 46.8% over the trailing 30 days and 78.0% over 90 days. His cross-ticker track record shows strong performance (91.67% win rate on buys, +46.5% avg 30d return, +55.6% avg 90d return), but his 5 most recent prior purchases at this same ticker (May 28–June 3) remain too recent to assess outcomes. The company reported net income of $-14.2M against $17.5M quarterly revenue, indicating ongoing losses and raising questions about the sustainability of the recent price recovery that has characterized the buying window.

Director Encrantz Staffan bought 98,782 shares across 3 trades (May 30–June 3) at blended $3.81, increasing holdings 8.5% to 1,256,487 shares

Encrantz Staffan, a director at Sight Sciences, executed 3 separate purchases totaling 98,782 shares for $376,429.44 over a four-day window at an average price of $3.81 per share. The stock has since risen 31.8% over 30 days and 66.1% over 90 days from the transaction dates, and currently trades at $4.02, up from the 52-week low of $2.09 but still -51.6% from the 52-week high of $8.31. Encrantz's cross-ticker track record shows 15 prior buys with a 91.67% win rate at the 90-day mark, though at this specific ticker (SGHT), prior trades have been mixed—a November 2024 buy-and-sell pair both showed -4.3% and -25.5% returns at 30 and 90 days, with 1 of 2 prior same-ticker trades well-timed at the 90-day mark. The company remains unprofitable (latest quarter net income: $-14,154,000.00) with near-flat annual revenue growth of -1.5%, and the market cap is $207.8M.

Director Encrantz Staffan purchases 128,189 shares over 3 days at blended avg $3.52, raising holdings to 1,157,705 shares; SGHT -57.6% from 52-week high.

Director Encrantz Staffan executed 3 separate purchases totaling 128,189 shares for $451,734.06 over consecutive days (May 27–29, 2025) at prices ranging from $3.44 to $3.59, increasing his stake by 12.5% to 1,157,705 shares. The transaction occurred as the stock trades 57.6% below its 52-week high of $8.31, though recent momentum has been positive (30-day +11.8%, 90-day +32.8%). At the same ticker, prior trades show mixed outcomes: four of five recent transactions were well-timed at the 90-day mark, but his most recent SGHT buy (November 2024) deteriorated 25.5% over 90 days. The company remains unprofitable with a net loss of $14,154,000.00 against quarterly revenue of $17,508,000.00 and flat annual revenue growth (-1.5%). The scale of this purchase—increasing holdings by over 128K shares—combined with the 12-month low pricing context warrants observation of whether this accumulation signals confidence at depressed valuations or reflects opportunistic positioning ahead of potential operational inflection.

EVP R&D Raheja purchases 20,000 shares in 2 tranches at $2.72 and $2.60 while stock down 71.1% from 52-week high

Raheja Manohar K. made 2 separate purchases totaling 20,000 shares for $53,250.00 ($53.2K) at an average price of $2.66, increasing his holdings by 14.8% to 155,000 shares. The current stock price of $2.40 sits -71.1% below the 52-week high of $8.31, with the stock having declined 9.8% over 30 days and 33.0% over 90 days. Raheja's prior trades at SGHT show a consistent pattern of poor timing: his 4 preceding buys at this ticker (December 6, December 3, November 29, and November 19) each generated negative 90-day returns ranging from -26.0% to -35.5%, with a 0% win rate. His cross-ticker track record is similarly weak, with 4 prior buys averaging -32.6% 90-day returns and 0% win rate. The company is unprofitable, with net income of $-11.1M on revenue of $20.2M, and recorded negative annual revenue growth of -1.5%.

EVP R&D buys 5,000 SGHT shares at $3.85; third purchase in 18 days amid -37.7% 90-day decline

Raheja Manohar K., EVP of Research & Development, purchased 5,000 shares of Sight Sciences at $3.85 on 2024-12-06, increasing his holdings to 111,000 shares. This is the third open-market purchase by this executive in the past 18 days (prior buys on 2024-12-03 and 2024-11-29), establishing a clear pattern of accumulation. The timing context is notable: the stock has declined -37.7% over the past 90 days and stands -52.0% below its 52-week high of $8.31, though it has recovered slightly (+5.7%) in the 30-day window. The company remains unprofitable with a net loss of $-11.1M in the latest quarter despite +13.6% annual revenue growth, so the repeated insider buying occurs against a backdrop of negative earnings and significant recent price weakness. The pattern of repeated small purchases at depressed prices warrants investor attention, particularly given the unprofitable operating context and volatility.

EVP R&D Raheja buys 3,376 shares of SGHT at $3.89; stock down -55.5% from 52-week high, company unprofitable

Raheja Manohar K., EVP of Research & Development, purchased 3,376 shares at $3.89 on 2024-12-03, adding to a position that has grown to 106,000 shares post-transaction. This marks his third open-market purchase at SGHT within two weeks—he also bought on 2024-11-29 and 2024-11-19. The timing context is notable: the stock is currently trading at $3.70, representing -55.5% from its 52-week high and -41.7% over the past 90 days. Sight Sciences remains unprofitable (net income $-11.1M against quarterly revenue of $20.2M) despite 13.6% annual revenue growth, a fundamental tension that warrants attention from investors tracking the path to profitability. The repeated buying pattern within a short window, combined with the severe drawdown from recent highs, is the key signal for monitoring.

EVP R&D Raheja Manohar K. bought 4,624 shares of SGHT at $3.99; stock -53.6% from 52-week high, company unprofitable.

Raheja Manohar K., EVP of Research & Development, purchased 4,624 shares at $3.99 on 2024-11-29, adding to holdings of 102,624 shares post-transaction. The purchase occurs in a context of pronounced stock weakness: the current price of $3.86 sits at -53.6% from the 52-week high of $8.31, and the stock has declined -25.9% over the past 30 days and -39.8% over 90 days. Sight Sciences remains unprofitable (net income of $-11.1M on quarterly revenue of $20.2M), though the company posted +13.6% annual revenue growth. This is Raheja's second consecutive buy within the filing window (a prior buy on 2024-11-19 and another on 2024-12-03), but his cross-ticker track record shows only 2 prior open-market buys, with neither exhibiting positive 90-day outcomes. The outcomes of these same-ticker recent buys are not yet measurable.

Director Encrantz Staffan executes matched buy-sell of 551,802 shares at $3.73 on same day; holds 4,573,920 shares post-transaction.

Encrantz Staffan simultaneously purchased and sold 551,802 shares at $3.73 on 2024-11-21, resulting in zero net change to his position. This appears to be an exercise of options or conversion of restricted stock units into common shares, followed by an immediate market sale to fund the exercise cost or for tax withholding purposes. The transaction does not reflect a discretionary buy or sell decision: the purchase and sale prices are identical, executed on the same day, and the volumes match precisely, which is characteristic of option exercises or RSU conversions. His post-transaction holding of 4,573,920 shares remains substantial. The stock trades at $3.76 currently, down 54.8% from the 52-week high and down 33.4% over 30 days, but Encrantz's exercise activity carries no conviction signal—it is a mechanical cash-neutral transaction common to equity compensation events. Investors should not interpret this as a strategic buy or sell by the insider.